What IDE Group does

IDE Group is an Australian MedTech commercialisation and product development partner founded in 2003 by George Sidis and headquartered in Leichhardt, NSW, operating under the legal entity I D & E Pty Ltd. The firm offers end-to-end services spanning opportunity discovery, business strategy, product development, software solutions, quality assurance, regulatory affairs, manufacturing, market launch and distribution, human factors and usability engineering, plus a dedicated MedTech Simulation Usability Lab. Rather than a consulting or advisory model, IDE Group explicitly positions on a 'We do and build' execution approach, with a project portfolio that includes the OKO Ophthalmic Auto-Injector, Bayer's MEDRAD Centargo CT Injector, ResMed's Pixi pediatric sleep apnea mask, Unilife's Safety Syringe, and diagnostic and radiotherapy devices for Atomo Diagnostics, Truscreen, Visionsearch, and Nano-X.

The company serves five MedTech verticals — Connected Care, Drug Delivery, Point-of-Care Diagnostics, Surgical Devices, and Respiratory Care — and generates revenue through bespoke professional services engagements, with pricing not publicly disclosed. GTM is primarily enterprise field sales through direct client engagement with MedTech companies, pharmaceutical firms, and medical device startups. The company maintains a tri-regional delivery footprint across APAC (Leichhardt), Europe (Rotterdam), and North America (Newtown Square PA, Minneapolis MN), and runs the annual Building Better Futures for Health (BBFH) Challenge in conjunction with the MTAA MedTech Conference as an ecosystem and deal-sourcing mechanism.

No public revenue, ARR, or institutional funding history is disclosed. The firm received a $776,280 grant from MTPConnect in June 2025 and operates with a 101-250 employee base, implying a mid-sized private services firm in growth mode rather than a scaled platform.

Name

IDE Group

Legal name

I D & E Pty Ltd

Website

https://idegroup.com.au

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

101–250 employees

Short description

IDE Group is an Australian MedTech commercialisation and product development partner offering end-to-end services from design through regulatory, manufacturing, and market launch to medtech companies, pharma firms, and device startups across APAC, Europe, and North America.

Ownership category

akta.pro rank

Product category

Medical Device Design & Commercialisation Services

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Computer Systems Design Services (541512)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Health Services (8000)

akta.pro primary industry

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ)

Keywords

• Medtech product development
• Medical device commercialisation
• Regulatory affairs services
• Drug delivery development
• Human factors engineering

Headquarters

HQ city

Leichhardt

HQ country

Australia

HQ region

Oceania

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. MedTech Innovation & Commercialisation Services: IDE Group generates revenue through providing comprehensive MedTech commercialisation services including product development, regulatory affairs, manufacturing, and market launch support to medtech companies and pharmaceutical partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

IDE Group is a MedTech commercialisation and innovation partner that provides end-to-end services for medical device companies and pharmaceutical partners. The company operates across the full product lifecycle — opportunity discovery, business strategy, product development, software solutions, quality assurance, regulatory affairs, manufacturing, market launch and distribution, and human factors/usability engineering — across five MedTech sectors: Connected Care, Drug Delivery, Point-of-Care Diagnostics, Surgical Devices, and Respiratory Care. The firm also owns the proprietary OKO Ophthalmic Auto-Injector brand.

Product overview

IDE Group is a MedTech commercialization and innovation partner offering end-to-end services across five key sectors: Connected Care, Drug Delivery, Point-of-Care Diagnostics, Respiratory Care, and Surgical Devices. Rather than a single unified product, IDE Group operates as a service provider delivering specialized capabilities including opportunity discovery, business strategy, product development, software solutions, quality assurance, regulatory affairs, manufacturing, and market launch. Their portfolio consists of client-developed products including the OKO Ophthalmic Auto-Injector, MEDRAD Centargo CT Injector, Atomo Diagnostics HIV Rapid Test, Unilife Safety Syringe, Truscreen Cervical Cancer Screening, Visionsearch Bioamplifier, ResMed Pixi Mask, and Nano-X Patient Rotation System. They also operate a Simulation Usability Lab in Minneapolis for human factors testing.

Differentiator

Problem solved

Functional benefit

Brands

• OKO: A breakthrough auto-injection system for ophthalmic drug delivery, ensuring accurate dosing, safer procedures, and faster workflows.

Products and services

• MedTech End-to-End Commercialisation Services Integrated product development, regulatory affairs, manufacturing, and market launch services for medical device and pharmaceutical companies. Spans opportunity discovery, business strategy, product development, software solutions, quality assurance, regulatory affairs, manufacturing, and market launch and distribution across Connected Care, Drug Delivery, Point-of-Care Diagnostics, Surgical Devices, and Respiratory Care sectors.
• MedTech Simulation Usability Lab State-of-the-art facility located in Minneapolis, USA, providing human factors and usability engineering testing and validation for medical devices with real-world simulation capabilities. Offered to medical device manufacturers needing formal human factors validation as part of regulatory submissions.
• OKO Ophthalmic Auto-Injector A proprietary breakthrough auto-injection system for ophthalmic drug delivery developed by IDE Group under its OKO sub-brand. Ensures accurate dosing, safer procedures, and faster workflows, improving patient outcomes and enhancing clinic productivity. The device is positioned for ophthalmology clinics and pharmaceutical partners delivering ophthalmic therapeutics.

Quantifiable outcome

• Successful commercialisation of multiple medical devices including OKO auto-injector, MEDRAD Centargo CT Injector, ResMed Pixi Mask

Named customers7 records

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Product Creation Studio: US-based product development firm specialising in medical devices, wearables, and connected health — directly comparable to IDE Group's connected care and surgical devices verticals with similar mid-market positioning.
• Triple Ring Technologies: US MedTech and life sciences product development and regulatory services firm serving startups through large device manufacturers — overlaps IDE Group's mix of early-stage and enterprise clients across diagnostics, surgical, and connected care segments.
• Gilero: US-based medical device and drug delivery product design and contract manufacturing firm — directly comparable to IDE Group's drug delivery, point-of-care diagnostics, and combination product development offerings.
• Veranex (formerly Ximedica): PE-backed global MedTech design, development, and commercialisation services platform combining Ximedica, Quartesian, and other acquired firms — competes head-to-head with IDE Group for enterprise medical device development and regulatory engagements.
• Mindflow Design: Mid-sized MedTech product development consultancy offering mechanical, software, and regulatory services — comparable in scale and service breadth to IDE Group, particularly across surgical and diagnostic device programmes.
• HS Design: US MedTech product development firm specialising in design, human factors, and regulatory services for medical devices — comparable in service mix, size tier, and therapeutic focus to IDE Group's surgical, diagnostic, and respiratory verticals.
• StarFish Medical: Canadian MedTech product development firm providing end-to-end design, engineering, regulatory, and manufacturing services — directly comparable to IDE Group's 'opportunity discovery to market launch' value proposition across similar client segments and therapeutic areas.

Broad incumbents

• Battelle: Large applied science and technology development organisation with a significant medical device and life sciences practice — broader and better-capitalised than IDE Group but competes for complex MedTech commercialisation mandates.
• Cambridge Consultants: Large UK-based technology consultancy with a deep MedTech practice covering product development, human factors, and regulatory — broader portfolio than IDE Group but directly overlapping on complex medical device and drug delivery programmes.

Others

• Medical Device Usability: Specialised human factors and usability engineering consultancy serving the MedTech industry — adjacent rather than directly competitive, but overlaps with IDE Group's Simulation Usability Lab capability in Minneapolis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/ide_group
• Facebookfacebook.com/ideconnect
• LinkedInlinkedin.com/company/ide-

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IDE Group